Study suggests favipiravir benefits for Ebola patients
A trial of the antiviral drug favipiravir in Ebola patients during Sierra Leone's outbreak suggests that it can reduce viral load, improve clinical symptoms, increase the survival rate, and prolong survival time, Chinese and African researchers reported yesterday in Clinical Infectious Diseases (CID).